LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 1 von insgesamt 1

Suchoptionen

Artikel ; Online: Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient with Richter Transformation: A Case Report and Review of the Literature.

Parigger, Thomas / Drothler, Stephan / Scherhäufl, Christian / Gassner, Franz Josef / Schubert, Maria / Steiner, Markus / Höpner, Jan Philip / Hödlmoser, Alexandra / Schultheis, Lena / Abu Bakar, Aryunni / Neureiter, Daniel / Pleyer, Lisa / Egle, Alexander / Greil, Richard / Geisberger, Roland / Zaborsky, Nadja

Acta haematologica

2024  

Abstract: Introduction: Targeting the B cell receptor (BCR) pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred ... ...

Abstract Introduction: Targeting the B cell receptor (BCR) pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates.
Case presentation: In this study, we performed exome and transcriptome analyses of an ibrutinib resistant CLL patient in order to investigate genes and expression patterns associated with ibrutinib resistance. Here we provide evidence that ibrutinib resistance can be attributed to aberrant mammalian target of rapamycin (MTOR) signaling.
Conclusion: Thus, our study proposes that combined use of MTOR inhibitors with ibrutinib could be a possible option to overcome therapy resistance in ibrutinib treated patients.
Sprache Englisch
Erscheinungsdatum 2024-02-24
Erscheinungsland Switzerland
Dokumenttyp Case Reports
ZDB-ID 80008-9
ISSN 1421-9662 ; 0001-5792
ISSN (online) 1421-9662
ISSN 0001-5792
DOI 10.1159/000537791
Signatur
Ud II Zs.145: Hefte anzeigen Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Kategorien

Zum Seitenanfang